Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

James A Underberg

Showing results (1-10 of 29) with videos related to

Pageof 3
Sort By:
The Journal of Family Practice|August 2, 2008
Bridging the gap in treatment options for patients with hypertriglyceridemiaJames A Underberg, Richard Hays
Clinical Pharmacology and Therapeutics|June 9, 2018
Lowering LDL-Cholesterol and CV Benefits: Is There a Limit to How Low LDL-C Needs to be for Optimal Health Benefits?Anish Vani, James A Underberg
Current Atherosclerosis Reports|October 18, 2017
The Use of Primary Prevention Statin Therapy in Those Predisposed to AtherosclerosisMichael Garshick, James A Underberg
Cardiovascular Drugs and Therapy|July 30, 2013
Systematic review: Evaluating the effect of lipid-lowering therapy on lipoprotein and lipid valuesRobert S Rosenson, James A Underberg
Current Atherosclerosis Reports|February 19, 2015
The recent national lipid association recommendations: how do they compare to other established dyslipidemia guidelines?Laura Flink, James A Underberg, Jonathan D Newman, et al.
Journal of Clinical Lipidology|March 25, 2023
JCL Roundtable: From Gen Med to Clinical LipidologyKaye-Eileen Willard, Daniel Soffer, James A Underberg, et al.
Postgraduate Medicine|July 17, 2016
Focus on PCSK9 Inhibitors: From Genetics to Clinical PracticeMarc S Sabatine, James A Underberg, Michael Koren, et al.
Journal of Clinical Lipidology|December 7, 2016
JCL roundtable: Risk evaluation and mitigation strategyW Virgil Brown, Dean A Bramlet, Joyce L Ross, et al.
The American Journal of Medicine|July 26, 2017
Developing Optimized Treatment Plans for Patients with Dyslipidemia in the Era of Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitor TherapeuticsJames A Underberg, Michael J Blaha, Elizabeth J Jackson, et al.
Journal of Clinical Lipidology|May 16, 2017
Dapagliflozin in patients with type II diabetes mellitus, with and without elevated triglyceride and reduced high-density lipoprotein cholesterol levelsHarold E Bays, Peter Sartipy, John Xu, et al.
Pageof 3

Showing results (1-10 of 29) with videos related to

Sort By:
Pageof 3
The Journal of Family Practice|August 2, 2008
Bridging the gap in treatment options for patients with hypertriglyceridemiaJames A Underberg, Richard Hays
Clinical Pharmacology and Therapeutics|June 9, 2018
Lowering LDL-Cholesterol and CV Benefits: Is There a Limit to How Low LDL-C Needs to be for Optimal Health Benefits?Anish Vani, James A Underberg
Current Atherosclerosis Reports|October 18, 2017
The Use of Primary Prevention Statin Therapy in Those Predisposed to AtherosclerosisMichael Garshick, James A Underberg
Cardiovascular Drugs and Therapy|July 30, 2013
Systematic review: Evaluating the effect of lipid-lowering therapy on lipoprotein and lipid valuesRobert S Rosenson, James A Underberg
Current Atherosclerosis Reports|February 19, 2015
The recent national lipid association recommendations: how do they compare to other established dyslipidemia guidelines?Laura Flink, James A Underberg, Jonathan D Newman, et al.
Journal of Clinical Lipidology|March 25, 2023
JCL Roundtable: From Gen Med to Clinical LipidologyKaye-Eileen Willard, Daniel Soffer, James A Underberg, et al.
Postgraduate Medicine|July 17, 2016
Focus on PCSK9 Inhibitors: From Genetics to Clinical PracticeMarc S Sabatine, James A Underberg, Michael Koren, et al.
Journal of Clinical Lipidology|December 7, 2016
JCL roundtable: Risk evaluation and mitigation strategyW Virgil Brown, Dean A Bramlet, Joyce L Ross, et al.
The American Journal of Medicine|July 26, 2017
Developing Optimized Treatment Plans for Patients with Dyslipidemia in the Era of Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitor TherapeuticsJames A Underberg, Michael J Blaha, Elizabeth J Jackson, et al.
Journal of Clinical Lipidology|May 16, 2017
Dapagliflozin in patients with type II diabetes mellitus, with and without elevated triglyceride and reduced high-density lipoprotein cholesterol levelsHarold E Bays, Peter Sartipy, John Xu, et al.
Pageof 3